{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:24:56Z","timestamp":1780604696449,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021729","name":"Faculty of medicine, University of Freiburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021729","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e4ts-Herzzentrum Freiburg - Bad Krozingen GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High on-clopidogrel platelet reactivity (HPR) associates with ischemic risk in patients after percutaneous intervention (PCI). This study aimed to evaluate the association of HPR as assessed by multiple electrode aggregometry (MEA) with ischemic, thromboembolic, and bleeding risk in patients with atrial fibrillation (AF) undergoing PCI. Patients with AF and an indication for oral anticoagulation (OAC) were included in this prospective cohort study on day 1\u20133 after PCI. Platelet aggregation [U] was analyzed by MEA. HPR and low platelet reactivity (LPR) were defined as ADP-induced aggregation\u2009\u2265\u200946\u00a0U and\u2009\u2264\u200918\u00a0U, respectively. TRAP-6-induced aggregation reference was 94\u2013156\u00a0U. The primary outcome was time to all-cause death, myocardial infarction, or stroke at 6\u00a0months. The secondary outcome was time to non-major clinically relevant bleedings or major bleedings. 159 patients were enrolled between May 2020 and May 2021. The median age was 78\u00a0years (interquartile range 72\u201382) and 111 (70%) were male. Median ADP- and TRAP-induced aggregation were 12 (6\u201317) and 49 (35\u201368) U, respectively. 147 (93%) patients had a low overall aggregability. HPR was detected in 2 patients (1%) and 125 (79%) had LPR. ADP-induced aggregation did not significantly associate with the primary outcome (r\u2009=\u20090.081, p\u2009=\u20090.309) but correlated inversely with bleeding risk (r\u2009=\u2009\u2212\u00a00.201, p\u2009=\u20090.011). HPR status as assessed by MEA among patients with AF after PCI was rare and overall aggregability was low. Conventional cut-off values for HPR might be inappropriate for these patients. ADP-induced aggregation might be helpful to identify patients at risk for bleeding.<\/jats:p>","DOI":"10.1007\/s11239-023-02937-0","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T21:02:46Z","timestamp":1707771766000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low on-clopidogrel ADP- and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study"],"prefix":"10.1007","volume":"57","author":[{"given":"Diona","family":"Gjermeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Anfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hesselbarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Gauchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leggewie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph B.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"issue":"5","key":"2937_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"2","key":"2937_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"F-J Neumann","year":"2019","unstructured":"Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al (2019) 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J 40(2):87\u2013165","journal-title":"Eur Heart J"},{"issue":"3","key":"2937_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/14740338.2018.1424827","volume":"17","author":"CB Olivier","year":"2018","unstructured":"Olivier CB, Turakhia MP, Mahaffey KW (2018) Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. Expert Opin Drug Saf 17(3):251\u2013258","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"2937_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380(16):1509\u20131524","journal-title":"N Engl J Med"},{"issue":"5","key":"2937_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","volume":"5","author":"RD Lopes","year":"2020","unstructured":"Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP et al (2020) Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol 5(5):582\u2013589","journal-title":"JAMA Cardiol"},{"issue":"10206","key":"2937_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet 394(10206):1335\u20131343","journal-title":"The Lancet"},{"issue":"16","key":"2937_CR7","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377(16):1513\u20131524","journal-title":"N Engl J Med"},{"issue":"25","key":"2937_CR8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375(25):2423\u20132434","journal-title":"N Engl J Med"},{"issue":"9872","key":"2937_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, Smet BJD, Herrman J-P et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet 381(9872):1107\u20131115","journal-title":"The Lancet"},{"issue":"5","key":"2937_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jacc.2021.11.035","volume":"79","author":"RE Harskamp","year":"2022","unstructured":"Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE et al (2022) Antithrombotic therapy in patients with atrial fibrillation after acute coronary syndromes or percutaneous intervention. J Am Coll Cardiol 79(5):417\u2013427","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2937_CR11","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","volume":"8","author":"LR Jackson","year":"2015","unstructured":"Jackson LR, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW et al (2015) Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of Clopidogrel Versus Prasugrel from the TRANSLATE-ACS study. JACC Cardiovasc Interv 8(14):1880\u20131889","journal-title":"JACC Cardiovasc Interv"},{"issue":"20","key":"2937_CR12","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","volume":"61","author":"N Sarafoff","year":"2013","unstructured":"Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D et al (2013) Triple therapy with aspirin, prasugrel, and Vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 61(20):2060\u20132066","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2937_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12872-018-0853-x","volume":"18","author":"C Hu","year":"2018","unstructured":"Hu C, Zhang X, Liu Y, Gao Y, Zhao X, Zhou H et al (2018) Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study. BMC Cardiovasc Disord 18(1):120","journal-title":"BMC Cardiovasc Disord"},{"issue":"16","key":"2937_CR14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L et al (2019) Updated expert consensus statement on platelet function and genetic testing for Guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 12(16):1521\u20131537","journal-title":"JACC Cardiovasc Interv"},{"issue":"27","key":"2937_CR15","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","volume":"36","author":"D Aradi","year":"2015","unstructured":"Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36(27):1762\u20131771","journal-title":"Eur Heart J"},{"issue":"9892","key":"2937_CR16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F-J, Metzger DC et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614\u2013623","journal-title":"Lancet"},{"issue":"10104","key":"2937_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. The Lancet 390(10104):1747\u20131757","journal-title":"The Lancet"},{"issue":"9","key":"2937_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","volume":"137","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B et al (2018) Cardiovascular and stroke endpoint definitions for clinical trials. Circulation 137(9):961\u2013972","journal-title":"Circulation"},{"key":"2937_CR19","doi-asserted-by":"crossref","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015; 13(11):2119\u201326.","DOI":"10.1111\/jth.13140"},{"key":"2937_CR20","doi-asserted-by":"crossref","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692\u20134.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"issue":"10","key":"2937_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","volume":"53","author":"D Sibbing","year":"2009","unstructured":"Sibbing D, Braun S, Morath T et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53(10):849\u2013856","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2937_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s11239-016-1397-5","volume":"42","author":"J Rilinger","year":"2016","unstructured":"Rilinger J, Meyer M, Schnabel K, Weik P, Charlet A, Esser JS et al (2016) High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. J Thromb Thrombolysis 42(4):558\u2013565","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"2937_CR23","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/jcm10081565","volume":"10","author":"J Gruttemeier","year":"2021","unstructured":"Gruttemeier J, Cottin Y, Yao H, De Maistre E, Maza M, Bonello L et al (2021) Impact of platelet reactivity in acs patients on clinical outcomes with triple antithrombotic therapy. J Clin Med 10(8):1565","journal-title":"J Clin Med"},{"issue":"10","key":"2937_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/ehq023","volume":"31","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N et al (2010) Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 31(10):1205\u20131211","journal-title":"Eur Heart J"},{"key":"2937_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/798486","volume":"2015","author":"AM Martischnig","year":"2015","unstructured":"Martischnig AM, Mehilli J, Pollak J, Petzold T, Fiedler AK, Mayer K et al (2015) Impact of dabigatran versus phenprocoumon on ADP induced platelet aggregation in patients with atrial fibrillation with or without concomitant clopidogrel therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). Biomed Res Int 2015:1\u201310","journal-title":"Biomed Res Int"},{"key":"2937_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.thromres.2015.10.038","volume":"138","author":"CB Olivier","year":"2016","unstructured":"Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P et al (2016) TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thromb Res 138:63\u201368","journal-title":"Thromb Res"},{"issue":"3","key":"2937_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/jth.13595","volume":"15","author":"A Achilles","year":"2017","unstructured":"Achilles A, Mohring A, Dannenberg L, Grandoch M, Hohlfeld T, Fischer JW et al (2017) Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. J Thromb Haemost 15(3):473\u2013476","journal-title":"J Thromb Haemost"},{"issue":"01","key":"2937_CR28","doi-asserted-by":"publisher","first-page":"083","DOI":"10.1055\/s-0039-1695772","volume":"120","author":"F Franchi","year":"2020","unstructured":"Franchi F, Rollini F, Garcia E, Rivas Rios J, Rivas A, Agarwal M et al (2020) Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT Study. Thromb Haemost 120(01):083\u2013093","journal-title":"Thromb Haemost"},{"issue":"14","key":"2937_CR29","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.3390\/jcm11144237","volume":"11","author":"D Gjermeni","year":"2022","unstructured":"Gjermeni D, Vetter H, Szab\u00f3 S, Anfang V, Leggewie S, Hesselbarth D et al (2022) Thrombelastography compared with multiple impedance aggregometry to assess high on-clopidogrel reactivity in patients with atrial fibrillation undergoing percutaneous coronary intervention. JCM 11(14):4237","journal-title":"JCM"},{"issue":"11","key":"2937_CR30","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1160\/TH15-03-0257","volume":"114","author":"TG N\u00fchrenberg","year":"2015","unstructured":"N\u00fchrenberg TG, Stratz C, Leggewie S, Hochholzer W, Valina CM, Gick M et al (2015) Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation: An ADAPT-DES substudy. Thromb Haemost 114(11):1020\u20131027","journal-title":"Thromb Haemost"},{"key":"2937_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11239-022-02720-7","volume":"55","author":"D Hesselbarth","year":"2022","unstructured":"Hesselbarth D, Gjermeni D, Szabo S, Siegel PM, Diehl P, Moser M et al (2022) Time from blood draw to multiple electrode aggregometry and association with platelet reactivity. J Thromb Thrombolysis 55:134","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2937_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacc.2014.03.051","volume":"64","author":"W Hochholzer","year":"2014","unstructured":"Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L et al (2014) Variability of individual platelet reactivity over time in patients treated with clopidogrel. J Am Coll Cardiol 64(4):361\u2013368","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02937-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T20:03:22Z","timestamp":1711310602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2937"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02937-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"16 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CBO reports research support from Haemonetics, Deutsche Forschungsgemeinschaft, Faculty of Medicine, Freiburg University; Else Kr\u00f6ner-Fresenius Stiftung; honoraria: Bayer Vital GmbH, Daiichi Sankyo, Ferrer, Idorsia. KF reports honoraria and congress sponsoring by Bayer Vital GmbH and Novartis Pharma GmbH. DT reports research support by a grant from Deutsche Herzstiftung. He received within the last 24\u00a0months consulting fees\/payment for lectures including service on speakers\u2019 bureaus by Alexion Pharma, Amgen, AstraZeneca, Atriva, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Ferrer, Pfizer and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}